Moderna's Melanoma Timeline Extends to 2028 as Analysts Split on What the Rally Is Worth
Published on 11/03/2026 at 14:41 | Editorial boerse-global.de
Moderna's personalized cancer therapy could reach patients in Germany and Europe by 2028 — but that date describes a potential launch, not an approval already in hand. The timeline covers the combination of Moderna's intismeran autogene with Merck's Keytruda, and it lands alongside a Wall Street debate that has produced two very different verdicts on the same stock.
A 42% Risk Cut, With Overall Survival Still Maturing
Roughly two weeks ago, the two companies unveiled detailed results from the Phase 3 INTerpath-001 trial, which enrolled 1,137 patients with surgically removed Stage IIB to IV melanoma. The combination cut the risk of recurrence or death by 42% versus Keytruda alone, and lowered the risk of distant metastasis or death by 38%.
After a median follow-up of 24.6 months, the overall survival data had not yet matured. The companies said they remain in contact with regulatory authorities. The detailed results were published ahead of schedule after data leaked publicly — a disclosure that preceded the release and shaped the market's reception.
Should investors sell immediately? Or is it worth buying Moderna?
Why the Stock Slipped Despite Positive Data
Reuters characterized the share price reaction at the time as profit-taking following a months-long rally. The 42% reduction on the recurrence-or-death endpoint also fell short of the 49% seen in an earlier Phase 2b study, a gap that gave investors room to trim positions after a strong run.
Two Houses, Two Readings of the Same Rally
William Blair downgraded Moderna from "Outperform" to "Market Perform" on October 27, citing valuation after the sharp share price advance. Analyst Myles Minter tied the company's further commercial potential to results in other tumor types, where he flagged substantial clinical and biological risks. Those concerns explicitly extend beyond the melanoma indication under study.
Piper Sandler moved the other way. On October 26, the firm lifted its price target on Moderna to $230 from $167 while keeping its "Overweight" rating. The higher target came without any change to the investment verdict — a contrast with William Blair, which used valuation as grounds for a more cautious stance.
November 6 Becomes the Next Confirmed Marker
With the clinical news out and the analyst actions logged, attention shifts to Moderna's third-quarter 2026 financial results, scheduled for release on November 6, 2026. It is the next confirmed company date on the calendar, and the first hard look at the business since the melanoma data and the split analyst response.
Ad
Moderna Stock: New Analysis - 3 November
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
